Neurogenetic studies show proprietary compound reduces brain plaques linked to Alzheimer's
Researchers found that NGP 555 selectively targets gamma secretase, reducing Aβ42 and amyloid pathology in a transgenic mouse model. Chronic administration led to significant reduction in diffuse and neuritic plaques without GI side effects.